Most people with scleroderma have autoantibodies. Several scleroderma-specific antibodies have been identified. These can help with diagnosis and give insight into the type of disease you may ...

Plant-derived monoclonal antibodies (mAbs) are being explored as potential therapeutic strategies due to their diverse mechanisms of antiviral activity. MPXV produces two key infectious particles: the ...

GSK was the first to market when its BLyS-specific inhibitor Benlysta was approved by the FDA in 2011. It has since become a blockbuster medicine, while AstraZeneca’s more recent challenger ...

In a new study, researchers examined four randomized controlled trials of belimumab (Benlysta®) to gain a better understanding of systemic lupus erythematosus (SLE) active disease progression with the ...

"Most therapeutic antibodies target a single viral site and lose effectiveness within a year as new variants appear. AMETA, however, is designed to bind to multiple conserved regions of the virus ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and ...

About clesrovimab (MK-1654) Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV. Clesrovimab is ...

Researchers at Fred Hutchinson Cancer Center, led by Dr. Julie McElrath, Director of the Vaccine and Infectious Disease Division, have found a new way to train our immune system to make antibodies ...